Merus (MRUS) PT Doubled to $32 at Wedbush Amid Incyte Deal
FREE Breaking News Alerts from StreetInsider.com!
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Incyte and Merus Announce Global Strategic Research Collaboration to Discover and Develop Bispecific Antibodies
December 21, 2016 7:00 AM ESTCollaboration designed to leverage Merus Biclonics® bispecific antibody technology to expand Incytes discovery capabilities and large-molecule portfolio Incyte to make up-front payment of $120 million and purchase $80 million of Merus common shares; Merus eligible to receive potential development, regulatory and commercial milestones and sales royalties Merus conference call scheduled today at 8:30 a.m. ET, 2:30 p.m. CET
WILMINGTON, Del. & UTRECHT, Netherlands--(BUSINESS WIRE)-- Incyte Corporation (NASDAQ: INCY) and Merus N.V. (NASDAQ: MRUS) announced... More
